II. How to Use

When to Use

Use the Revised Geneva Score to risk-stratify patients with suspected pulmonary embolism (PE) and provide an estimated pre-test probability. This score helps clinicians determine if further testing, such as a D-dimer or CT angiogram (CTA), is necessary.

Pearls / Pitfalls

Unlike the Wells score, the Revised Geneva Score is based entirely on objective variables, eliminating the “subjective” criterion often criticized in Wells (“PE #1 diagnosis or equally likely”).

Meta-analyses suggest that the Wells score may demonstrate slightly higher sensitivity than the Revised Geneva score for identifying pulmonary embolism, although overall diagnostic performance is comparable. Both tools should be applied only in patients with clinical suspicion for PE.

Why Use

It is endorsed by major societies, including the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), as an alternative to the Wells score for pre-test probability assessment.

III. Next Steps

Advice

Integrating the PERC Rule: For patients identified as “low-risk” by the clinical score, clinicians may consider applying the PERC (Pulmonary Embolism Rule-out Criteria). If a patient is low-risk and meets all PERC criteria, the workup for PE can potentially be stopped without obtaining a D-dimer.

Age-Adjusted D-dimer: For patients over the age of 50 who are classified as “not high risk” (Revised Geneva score <11), use an age-adjusted D-dimer cutoff to increase specificity. The validated formula is Age (years) x 10 µg/L. Using this age-adjusted strategy, rather than a standard cutoff, has been shown to be safe and sensitive in ruling out PE.

Score Comparison: Meta-analyses suggest that the Wells score may demonstrate slightly higher sensitivity than the Revised Geneva score for identifying pulmonary embolism, although overall diagnostic performance is comparable. This difference is thought to be partly due to the inclusion of a clinician gestalt component (“PE most likely”) in the Wells score, which may enhance sensitivity by capturing features not reflected in structured variables. However, the magnitude of this difference is modest (approximately 5–10% higher sensitivity in some analyses), and the Revised Geneva Score offers the advantage of complete objectivity and reproducibility. In practice, both tools are acceptable; selection may depend on whether a clinician prefers a fully standardized approach (Revised Geneva) or incorporation of clinical judgment (Wells).

Impact on Imaging

Utilizing a formal clinical flowchart that incorporates these scores (Revised Geneva Score or Wells score) alongside the PERC rule and D-dimer testing has been associated with a significant reduction in radiologic imaging without increasing the rate of missed diagnoses.

Figure (Text-Based): Diagnostic Algorithm for Suspected PE

Clinical Decision Pathway for Suspected Pulmonary Embolism

  1. Clinical Suspicion of PE: Apply only if PE is reasonably suspected based on history and exam.

  2. Assess Pre-Test Probability (Revised Geneva Score or Wells score)

    • Classify as:

      • Low / Intermediate / High (three-tier), or

      • PE Unlikely / PE Likely (two-tier)

  3. If Low Risk (or PE Unlikely): Consider PERC Rule

    • If PERC negative → No further testing

    • If PERC positive → proceed to D-dimer

  4. D-dimer Testing

    • If negative → PE ruled out (no imaging)

    • If positive → proceed to imaging

    • For patients >50 years:

      • Use age-adjusted D-dimer (Age × 10 µg/L)

  5. If High Risk (or PE Likely)

    • Proceed directly to imaging (CT pulmonary angiography)

Special Populations: The Revised Geneva Score has not been well validated in pregnant patients and is not recommended as a standalone tool in this population. Pregnancy-adapted diagnostic algorithms (e.g., pregnancy-adapted YEARS) are preferred, as they incorporate clinical features and D-dimer thresholds specific to pregnancy.

Management

Advice

Clinical Suspicion Prerequisite: As with all clinical decision aids, a physician must first have a clinical suspicion of pulmonary embolism (PE) before applying the Revised Geneva Score. It is not intended to be a screening tool for all patients presenting with generic symptoms like chest pain or shortness of breath.

Two-Tier vs. Three-Tier Models: While both models are accepted, current guidelines (including the ACEP 2018 policy), favor the two-tier model (PE Unlikely vs. PE Likely). The two-tier model is preferred because “intermediate” risk patients in the three-tier model are often considered too high-risk to be safely evaluated without extensive further stratification.

Three-Tier Model

Low (0-3 points): Consider high-sensitivity D-dimer; if negative, stop workup

Intermediate (4-10 points): D-dimer or CTA

High (≥11 points): Proceed to CTA; D-dimer is not recommended

Two-Tier Model

PE Unlikely (0-5 points): High-sensitivity D-dimer

PE Likely (≥6 points): CTA

Critical Actions

Never delay resuscitation for diagnostic testing in unstable patients.

Always obtain a history and physical exam before applying clinical decision rules.

Clinical gestalt trumps decision making rules.

IV. Evidence

Evidence Appraisal

Comparative Effectiveness:
The Revised Geneva Score was derived and validated by Le Gal et al. (2006) in a prospective cohort of patients with suspected pulmonary embolism, stratifying patients into low (8%), intermediate (28%), and high (74%) probability groups. Subsequent validation studies confirmed its performance across Emergency Department (ED) populations. Multiple studies have demonstrated similar overall diagnostic accuracy between the Revised Geneva and Wells scores, with comparable area under the curve (AUC) values.

Comparative meta-analyses, including a systematic review and Bayesian network meta-analysis of 11 studies, suggest that the Wells score may demonstrate slightly higher sensitivity than the Revised Geneva Score for identifying pulmonary embolism, although overall diagnostic performance is comparable. Reported sensitivity ranges from approximately 85–95% for the Wells score and 80–90% for the Revised Geneva Score, with modest specificity for both (approximately 40–60%), depending on the applied threshold and study population.

Reliability and Accuracy: The Revised Geneva Score is fully standardized and based entirely on objective variables, contributing to moderate-to-substantial interrater reliability and reproducibility across clinicians. Validation studies, including those by Klok et al. (2008), demonstrated that simplified versions of the score maintain similar diagnostic accuracy while improving usability. Although derivation studies were conducted in higher-prevalence populations (~30%), external validation in ED cohorts with lower disease prevalence (approximately 9.5%–12%) has confirmed its reliability and clinical utility.

Integration with Advanced Strategies: The evidence appraisal of the Revised Geneva Score now heavily involves the use of age-adjusted D-dimer cutoffs. Studies confirm that for patients identified as “not high risk” by the Revised Geneva Score (or “unlikely” by Wells), applying an age-adjusted cutoff (Age × 10 µg/L for patients >50 years) safely rules out PE while increasing diagnostic specificity.

Clinical Impact on Imaging

Implementation of structured diagnostic algorithms incorporating clinical probability assessment (using either the Revised Geneva Score or Wells score), the PERC rule, and D-dimer testing has been associated with significant reductions in imaging utilization (approximately 40%), without an increase in missed PE diagnoses. Available studies generally evaluate these strategies as integrated pathways rather than isolating the impact of individual clinical scores. As such, there is no consistent evidence demonstrating a meaningful difference in imaging rates or missed PE outcomes between the Revised Geneva and Wells scores when used within validated diagnostic algorithms.

Guideline Endorsement: Major societies, including the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorse the use of either the Revised Geneva Score or Wells score. They recommend that in patients with low or intermediate clinical probability and a negative (standard or age-adjusted) D-dimer, the workup can safely stop without radiologic imaging.

Formula

Addition of the selected points

Facts & Figures

Revised Geneva Score Points

  • Age ≥65 years: +1

  • Previous DVT or PE: +3

  • Surgery or lower-limb fracture within 1 month: +2

  • Active malignant neoplasm: +2

  • Unilateral lower-limb pain: +3

  • Hemoptysis: +2

  • Heart rate 75–94 bpm: +3

  • Heart rate ≥95 bpm: +5

  • Pain on deep vein palpation and unilateral edema: +4

Three-Tier Model

Low (0-3 points): Consider high-sensitivity D-dimer; if negative, stop workup

Intermediate (4-10 points): D-dimer or CTA

High (≥11 points): Proceed to CTA; D-dimer is not recommended

Two-Tier Model

PE Unlikely (0-5 points): High-sensitivity D-dimer.

PE Likely (≥6 points): CTA

Literature

Original/Primary & Validation

Le Gal G, et al. Prediction of Pulmonary Embolism in the Emergency Department: The Revised Geneva Score. Ann Intern Med. 2006.

Klok FA, et al. Simplification of the Revised Geneva Score for Assessing Clinical Probability of Pulmonary Embolism. Arch Intern Med. 2008.

Other References (including meta-analyses, CPGs, and impact analyses)

  1. Comparison of the Wells score with the Revised Geneva score for assessing suspected pulmonary embolism: a systematic review and meta-analysis. Journal of Thrombosis and Thrombolysis. https://link.springer.com/article/10.1007/s11239-015-1250-2.

  2. Bayesian Network Meta-Analysis Comparative diagnostic accuracy of pre-test clinical probability scores for the risk stratification of patients with suspected pulmonary embolism: A systematic review and Bayesian network meta-analysis. (n.d.). BMC Pulmonary Medicine. https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-025-03637-6

  3. American College of Emergency Physicians. (2018). ACEP clinical policy: Suspected acute venous thromboembolic disease. https://www.acep.org/siteassets/new-pdfs/clinical-policies/clinical.policy.suspected.acute.venous.thromboembolic.disease.pdf,

  4. European Society of Cardiology & European Respiratory Society. (n.d.). ESC/ERS guidelines for the diagnosis and management of acute pulmonary embolism.

  5. American Society of Hematology. (n.d.). ASH guidelines for management of venous thromboembolism.